Search 

DavosPharma’s corporate offering covers all the activities required to get a drug from conception to commercialization. DavosPharma has been filling this need since 1972, serving the pharmaceutical and life science market by providing discovery chemistry & biology, pre-clinical development, and all required CMC activities including custom synthesis of organic molecules, custom dosage formulation, and custom manufacturing of cGMP intermediates, APIs, and drug product. 

We are a Hong Kong-based venture fund management company focusing on mid- to long-term advanced technology investments at early stage. Through our partnership with the top analytical companies utilizing machine learning and large panel of experts, we can construct complex decision trees showing risk and return at every stage of company evolution. We routinely invest in both private and public companies specializing in biotechnology, drug discovery, personalized medicine, Big Data analysis, industrial expert systems and artificial intelligence. 

DELSIA is a "venture philanthropy" investment affilate of the research and advocacy foundation Autism Speaks. Our purpose is to transform lives by catalyzing the development and availability of innovative products.

DELSIA is a non-dilutive funding vehicle with the goal of improving outcomes for individuals with autism spectrum disorder (ASD). DELSIA aims to do this by enabling the translation of scientific breakthroughs and technological advances into products that improve health and quality of life for individuals with ASD and their families. 

Who and what do we invest in? DELSIA partners with for-profit companies to fund development activities necessary for delivering products that address the diverse unmet medical, behavioral health and quality of life needs of the autism community.

DELSIA accepts funding proposals from for-profit entities that include, but are not limited to:

• Entrepreneurs, start-up and small companies

• Life sciences, biotechnology and pharmaceutical companies

• Software, computer and electronic technology companies

DermSpectra has developed an innovative high resolution full body imaging system designed to aid early detection of skin cancers and diseases, and revolutionize medical documentation.  The DermSpectra Automated Total Body Digital Skin Imaging (DSI) System fills a key technology gap in medical imaging, empowers physicians with an objective tool to accurately and efficiently detect and monitor skin and body changes over time and raises the bar for patient care.

Deton is developing a novel non-invasive simple-to-use sample collection device for tuberculosis (TB) patients who are unable to provide a sample.

Proper diagnosis is essential to effectively treat the more than 9million new cases of TB every year. Typically, a sputum sample is collected to run the diagnostic test. However, in 22% of adults and in all children patients, sputum is impossible to collect. These patients have to rely on inadequate alternative collection methods that are invasive, high-cost, and resource-intensive. With our device, patients can now provide a sample even in low-resource setting and find out their TB status. Deton will enable 26M samples to be tested every year.

After promising clinical data, Deton is now raising $1.6M to build an ISO 13485 disposable product and to obtain pivotal clinical validation. Discussions with multiple potential diagnostic partners and first feedback from experts at World Health Organization show significant interest in adopting the device once effective validation has been completed. 

Diamond BioFund is an evergreen fund that was established in 2013 and is based in Taipei City, Taiwan. The fund is operating from a committed capital of USD 300 million. The fund makes equity investments in early- to late-stage private businesses. Typical allocations range from USD 1.5 million to north of USD 10 million. The fund likes to lead investments in Taiwan-based businesses and co-invest in businesses overseas. The fund is currently seeking new opportunities in Taiwan, Greater China, Southeast Asia, US, Canada, and EU.

Diamond BioFund takes a generalist approach when considering life science opportunities, including therapeutics (small molecule and biologics), medical devices, diagnostics, healthcare services, and nutraceuticals. The fund is seeking cutting edge, innovative, and platform technology. In therapeutics, the fund considers all stages from preclinical through pre-IPO. In medical devices, the fund prefers later stage projects with proof of concept. The fund is open to all disease indications.

Tania Fernandez is the founder of Dream Catcher Ventures, an advisory firm founded to address the inefficiencies in the marketplace and to align the goals and aspirations of entrepreneurs with investors in the healthcare/biotech sector. It is focused on creating and building disruptive biotech/healthcare companies that are positioned to excel in global markets. The firm also has a strong focus on biotech companies that have assets/technologies that are relevant to the Indian market.

Dr. Fernandez is currently working with BioHealth Innovation on a $50M “Gap Fund” to invest in seed and early stage healthcare/biotech companies primarily in therapeutics, diagnostics, medtech and healthcare IT.

Tania has a doctorate in molecular oncology and a post doctorate in protein chemistry and genetic engineering. She has over fifteen years of experience in the life sciences and 10 years of venture capital investing experience in biotech/ life sciences/healthcare and healthcare delivery.